100 related articles for article (PubMed ID: 7531274)
21. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation.
Platz KP; Mueller AR; Jonas S; Blumhardt G; Bechstein WO; Lobeck H; Neuhaus HL
Clin Transplant; 1995 Jun; 9(3 Pt 1):146-54. PubMed ID: 7549052
[TBL] [Abstract][Full Text] [Related]
22. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
23. Severe rhabdomyolysis and acute renal failure in a kidney transplant patient treated with tacrolimus and chimaeric CD25 monoclonal antibody.
Fontana I; Ginevri F; Basile G; Beatini M; Bertocchi M; Bonifazio L; Saltalamacchia L; Ghinolfi D; Santori G; Valente R; Perfumo F; Valente U
Transplant Proc; 2004 Apr; 36(3):711-2. PubMed ID: 15110640
[TBL] [Abstract][Full Text] [Related]
24. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation.
Paramesh AS; Grosskreutz C; Florman SS; Gondolesi GE; Sharma S; Kaufman SS; Fishbein TM
Transplantation; 2004 Jan; 77(1):129-31. PubMed ID: 14724447
[TBL] [Abstract][Full Text] [Related]
25. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation?
Lai WJ; Chiang YJ; Chen Y; Chu SH
Transplant Proc; 2004 Sep; 36(7):2056-7. PubMed ID: 15518744
[TBL] [Abstract][Full Text] [Related]
26. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
Campistol JM; Grinyó JM
Transplantation; 2001 Jun; 71(11 Suppl):SS42-51. PubMed ID: 11583488
[TBL] [Abstract][Full Text] [Related]
27. [Pro- and antitumor effects of the main immunosuppressive drugs used in the clinical practice of transplantation].
Marchini F
G Ital Nefrol; 2007; 24(2):171. PubMed ID: 17458835
[No Abstract] [Full Text] [Related]
28. The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.
Coates PT;
Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S85-7. PubMed ID: 17316286
[No Abstract] [Full Text] [Related]
29. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of the nephrotoxicity of immunosuppressive drugs with insulin-like growth factor-I].
Maestri M; Dionigi P; Pettenazza P; Visconti F; Rademacher J; Gaspari A; Innocente F; Matteotti C; Luzzana F; Zonta A
Minerva Chir; 1998 May; 53(5):391-6. PubMed ID: 9780630
[TBL] [Abstract][Full Text] [Related]
31. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
32. The nephrotoxicity of new and old immunosuppressive drugs.
Bennett WM
Ren Fail; 1998 Sep; 20(5):687-90. PubMed ID: 9768435
[TBL] [Abstract][Full Text] [Related]
33. Acute and chronic nephrotoxicity associated with immunosuppressive drugs.
Whiting PH
Curr Opin Nephrol Hypertens; 1994 Mar; 3(2):174-81. PubMed ID: 7531104
[TBL] [Abstract][Full Text] [Related]
34. Combination of immunosuppressive drugs for organ transplantation.
Ochiai T; Gunji Y; Nagata M; Isono K
Ann N Y Acad Sci; 1993 Nov; 696():270-80. PubMed ID: 7509136
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients.
Wang J; Guo R; Liu S; Chen Q; Zuo S; Yang M; Zuo X
Chin Med J (Engl); 2014; 127(20):3645-50. PubMed ID: 25316243
[TBL] [Abstract][Full Text] [Related]
36. Early detection of heart transplant patients with increased risk of ciclosporin nephrotoxicity.
Câmara NO; Matos AC; Rodrigues DA; Pereira AB; Pacheco-Silva A
Lancet; 2001 Mar; 357(9259):856-7. PubMed ID: 11265958
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506.
Ader JL; Rostaing L
Curr Opin Nephrol Hypertens; 1998 Sep; 7(5):539-45. PubMed ID: 9818201
[TBL] [Abstract][Full Text] [Related]
38. Cyclosporine nephrotoxicity.
Burdmann EA; Andoh TF; Yu L; Bennett WM
Semin Nephrol; 2003 Sep; 23(5):465-76. PubMed ID: 13680536
[TBL] [Abstract][Full Text] [Related]
39. Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A?
Hudnall SD
Transplantation; 2002 Sep; 74(6):757-8. PubMed ID: 12369583
[No Abstract] [Full Text] [Related]
40. Drug nephrotoxicity: an overview.
Bennett WM
Ren Fail; 1997 Mar; 19(2):221-4. PubMed ID: 9101595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
